Surmodics, Inc.
SRDX · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $1 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $1 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 5.3% | -6.1% | -9.9% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 71% | 72.1% | 75.2% | 73.9% |
| EBITDA | -$0 | -$0 | $0 | $0 |
| % Margin | -17.7% | -14.3% | 0.1% | 3% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -18% | -18.5% | -12.2% | -10.4% |
| EPS Diluted | -0.37 | -0.36 | -0.26 | -0.24 |
| % Growth | -2.8% | -38.5% | -8.3% | – |
| Operating Cash Flow | $0 | $0 | -$0 | $0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | $0 | -$0 | $0 |